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Abstract
Introduction
Having diabetes and smoking increases the risk of morbidity and mortality. However, cessation-related weight gain, a 
common side effect during quitting, can further complicate diabetes. Evidence-based telephone quitlines can support 
quitting but have not been studied adequately in populations with chronic diseases such as diabetes. The purpose of this 
study was to evaluate the use and effectiveness of a tobacco quitline among tobacco users with diabetes. Cessation-
related weight concerns and weight gain were also assessed.
Methods
We administered a telephone-based follow-up survey to tobacco users with and without diabetes 7 months after their 
enrollment in a quitline. We collected and analyzed data on demographics, tobacco use, dieting, weight concern, 
quitting success (7- and 30-day point prevalence), and weight gain. We computed summary statistics for descriptive 
data, χ and t tests for bivariate comparisons, and multivariable analyses to determine correlates of cessation.
Results
Tobacco users with diabetes used the quitline in a greater proportion than they were represented in the general 
population. Quit rates for those with and without diabetes did not differ significantly (24.3% vs 22.5%). No significant 
differences existed between groups for weight gain at follow-up, regardless of quit status. However, participants with 
diabetes reported more weight gain in previous quit attempts (34.2% vs 22.4% gained >20 lbs, P = .03). Weight concern 
was a significant correlate of continued smoking, regardless of diabetes status.
Conclusions
Results suggest that quitlines are effective for participants with diabetes, but tailored interventions that address weight 
concerns during cessation are needed.
Introduction
People with diabetes smoke at the same rate as people in the general population, despite excess health morbidity and 
mortality (1,2). In people with diabetes, cigarette smoking increases the risk of macrovascular complications, including 
circulatory, cardiovascular, and coronary heart disease (3,4), and microvascular complications, including kidney disease 
(5). Quitting smoking is essential to reduce the onset and exacerbation of diabetes (6).
However, weight gain is a potential barrier to successful quitting. It is common for people to gain 10 to 15 pounds after 
quitting (7,8) and those who are heavy smokers or are already overweight can gain considerably more (7,8). People with 
diabetes are more likely than those without diabetes to be overweight or obese (9), so excessive weight gain during 
cessation can present a substantial health hazard (10). In addition to actual weight gain, concern about gaining weight 
after quitting is common (11,12), and both hinder cessation (13,14). Although weight gain and weight concern are 
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important factors in the initiation and continuation of smoking, few data exist on the effect of weight-related issues on 
cessation in tobacco users with diabetes.
Numerous evidence-based resources exist to support successful quitting, including pharmacotherapy and counseling 
provided through state tobacco quitlines (15). Toll-free, telephone-based tobacco quitlines are 1 of the most cost-
effective treatment resources, yet even among the general population, they typically reach only 1% to 3% of smokers 
nationwide (16). Formative research suggests that people with diabetes have low awareness and use of effective 
cessation treatments including medication and quitlines (17). Although most cessation research has focused on the 
general population or related disease groups such as cardiovascular or lung disease (4), no published research has 
evaluated the use of a tobacco cessation quitline in a population of smokers with diabetes.
The primary purpose of this study was to describe the reach and effectiveness of a tobacco quitline among a sample of 
people with diabetes compared with those without the disease. A secondary aim was to assess the impact that concerns 
about weight gain have on quitting success.
Methods
Sample
Participants for this study were tobacco users aged 18 or older who called the Washington State Tobacco Quit Line (the 
quitline) from May through September 2008. For this cross-sectional study, we surveyed a census of tobacco users who 
reported a diagnosis of diabetes at the time of quitline registration and met other eligibility criteria and compared them 
with a matched group who registered for quitline services during the same period but did not report having diabetes. To 
control for differences that might affect quit rates (the dependent variable), we matched participants by sex, insurance 
status, and smoking dependence. Only 1 participant per household was included in the study; pregnant women were 
excluded because of the possibility of a pregnancy-related diabetes diagnosis.
At the time of data collection, the quitline offered free cessation services to any state resident aged 18 or older, including 
an initial counseling call of up to 30 minutes, self-management materials mailed to the caller, provision of nicotine 
patch or gum medication (if indicated), and referral to community-based cessation resources. The number of follow-up 
counseling calls (1 call vs up to 5 calls) and the amount of medication (2 vs 8 weeks) varied by population; uninsured, 
Medicaid-insured, and those referred from Veterans Affairs and Indian Health Services received the most intensive 
treatment options. Data on the Medicaid-insured population were available only for May and June because the state 
began offering separate Medicaid-only quitline services in July 2008. However, the separate Medicaid-only quitline 
services were available only for Medicaid fee-for-service participants. Other Medicaid participants may have been 
eligible for quitline services (and thus study recruitment) during the study period. This study was conducted by Alere 
Wellbeing in collaboration with the Washington State Department of Health with approval from the Western 
Institutional Review Board.
Data came from 1) information collected via telephone at the time of quitline registration, 2) a 7-month follow-up 
telephone survey, 3) automated process data collected at Alere Wellbeing (eg, number of counseling calls completed) 
and 4) comparison data from the 2008 Washington State Behavioral Risk Factor Surveillance System (BRFSS) survey. 
The 7-month follow-up telephone survey was administered from December 2008 through April 2009 by trained survey 
staff. To increase the survey response rate, a prenotification letter was mailed to participants about 10 days before 
survey administration. Participants were also offered a $20 gift card for completing the survey. If the interviewer could 
not reach a participant after 11 attempts, the survey was considered unanswered.
Measures and definition of concepts
Quitline registration data included participant demographics, tobacco use and cessation history, stage of readiness to 
quit, and prior use of pharmacotherapy. Chronic disease status was assessed by asking “Have you been diagnosed with 
any of the following chronic conditions: Asthma? Chronic obstructive pulmonary disease or emphysema? Diabetes? 
Heart disease?” Diabetes status was further clarified by asking participants if they had ever been told by a doctor that 
they had diabetes, a core question from the Centers for Disease Control and Prevention’s (CDC’s) 2007 Behavioral Risk 
Factor Surveillance System Survey (http://www.cdc.gov/brfss/). Participants who were prediabetic or were diagnosed 
with diabetes only during pregnancy were excluded from analyses.
Seven-day and 30-day tobacco point-prevalence quit rates were based on a respondent’s self-report of being tobacco-
free for the last 7 days or more, or 30 days or more at the time of the 7-month survey (18). Abstinence rates were 
computed by using both the responder and intent-to-treat methodology. Among continued smokers, intention to quit 
and reduction in amount of cigarettes smoked were also assessed.
Quitline use among tobacco users with diabetes was measured by a “reach effect ratio” based on the proportion of 
smokers aged ≥18) with diabetes who enrolled in quitline services in 2008 divided by the proportion of smokers with 
diabetes in the state (19). A reach ratio of 1.0 indicates that the quitline reaches the subgroup proportionally to its 
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distribution in the smoking population in that state; ratios less than 1 indicate lower reach and greater than 1 indicate 
higher reach.
Self-reported height and weight, physical activity, dieting, level of concern about gaining weight, perceived risk for 
relapse if they were to gain weight, prior weight gain due to quitting, perceived weight and change in weight, and 
postcessation weight change (among those who quit) were also measured.
Self-reported depression was assessed by using the Patient Health Questionnaire-2 (20): “Over the last 2 weeks how 
often have you been bothered by the following problems? 1- Having little interest or pleasure in doing things? 2- Feeling 
down, depressed or hopeless?” A mean score on the 2 items was computed, with the recommended cut point of 3 or 
more describing clinically significant depression (20). The mean score on 1 item was used to determine self-reported 
anxiety symptoms: “Over the last 2 weeks how often have you been bothered by: feeling nervous, anxious, or on the 
edge?” Panic was assessed with a yes/no question: “During the past 2 weeks did you have any episodes of panic or fear?”
Statistical analysis
Summary statistics were computed for descriptive data. Those who completed the survey were compared with those 
who did not to assess differences in individual characteristics. Chi-square and t tests were used for bivariate 
comparisons between groups. We conducted multiple logistic regression analyses by using SAS version 9.2 (SAS 
Institute Inc, Cary, North Carolina) to test for independent associations between the 2 groups in quit rates after 
controlling for demographic and tobacco use characteristics. Correlates of quitting were identified for the total sample 
and for the subsample with diabetes. Despite matching, sex was included in the multivariable analyses to control for 
possible selection bias (21), since both diabetes status (the key independent variable) and tobacco abstinence (the 
outcome variable) have been found to differ by sex (22). Less than 10% of responses were “do not know” or missing. 
These were omitted from the analyses. Significance was set at α =.05 for all analyses.
Results
Quitline use
According to the weighted prevalence rates from the 2008 BRFSS in Washington State, 15.7% (95% confidence interval 
[CI] = 15.0–16.4) of residents aged 18 or older smoked. No statistical difference in diabetes prevalence was found 
between adults who smoked and the general adult population in Washington (6.1% vs 6.0%, excluding those diagnosed 
only during pregnancy). Quitline registrations from 2008 showed that 8.3% (n = 1,077) of all adults who registered for 
quitline services reported a diagnosis of diabetes. This represents a quitline reach effect ratio of 1.36 (8.3%/6.1%), 
indicating that in Washington State, smokers with diabetes used the quitline in a higher proportion than they were 
represented in the general population of smokers.
Sample characteristics
Six hundred eligible tobacco users who registered for services with the quitline between May 1, 2008, and September 
30, 2008, were eligible to participate in the 7-month survey (261 participants with diabetes and 339 participants 
without diabetes) (Figure). After launching the survey, we learned that approximately 19% of identified participants had 
either disconnected or wrong telephone numbers. The survey response rate was 40.3%, yielding a final sample of 242 
participants (111 with diabetes, 131 without diabetes). Few differences existed between respondents and 
nonrespondents. Participants with diabetes were just as likely to complete the 7-month survey as those without diabetes 
(P = .34). Compared to nonrespondents, survey respondents were older (47.5 years vs 42.6 years; P < .001), less likely to 
be uninsured (10.7% vs 20.4%; P < .003), and more likely to have smoked for 20 years or more (75.6% vs 64.5%, P
< .01).
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Figure. Recruitment process for survey of eligible tobacco users who sought help from the Washington State Quit Line, 
May 2008–September 30, 2008. [A text description of this figure is also available.]
Respondents with diabetes were similar to those without diabetes in sex, race/ethnicity, education, insurance status, 
and current level of anxiety or panic (Table 1). Those with diabetes were older and more likely to report having 
significant depressive symptoms. Of the smokers with diabetes, 13% reported a diagnosis of type 1 diabetes, 78.9% 
reported a diagnosis of type 2 diabetes, and 8.2% reported they did not know. Both groups reported that the primary 
reason for calling the quitline was their desire or need to quit smoking, followed by advice to quit by family or health 
professionals.
Participants with diabetes did not differ from those without diabetes on the type of counseling call program (one call vs 
multiple calls); 41% of participants with diabetes and 45% of those without the disease enrolled in the multiple proactive 
counseling call program (up to 5 proactive counseling calls). No significant difference was found between groups in their 
satisfaction with quitline services or with their use of or satisfaction with quitline-provided nicotine replacement 
therapy (NRT). Approximately 68% of quitline users with diabetes used NRT compared with about 76% quitline users 
without diabetes.
Tobacco use characteristics
Most participants reported smoking cigarettes rather than other forms of tobacco (Table 1). Most were heavy, 
established smokers and more than half reported having their first cigarette of the day within 5 minutes of waking. 
Many also reported having other chronic diseases such as asthma, chronic obstructive pulmonary disease, or heart 
disease. Participants with diabetes reported smoking for significantly more years than those in the comparison group 
(86.2% vs 66.0% reported ≥20 years of smoking, P < .001) (Table 1).
Weight concern characteristics
Compared with participants without diabetes, participants with the disease were significantly more likely to be obese 
(56.9% vs 35.8% with BMI >30, P < .001) and to rate themselves as being very overweight (29.6% vs 12.7%, P < .001) 
(Table 1). Participants with diabetes did not differ from those without diabetes in dieting behaviors or physical activity 
levels. Although no differences in weight concern or perceived risk of relapse due to weight gain after quitting existed 
between participants with and without diabetes, nearly two-thirds of participants with diabetes were worried about 
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possible weight gain, although less than one-third thought they would return to smoking if they gained excessive weight 
after cessation.
Tobacco cessation outcomes
In bivariate analyses, participants with diabetes reported quit rates that were similar to those of participants without 
diabetes (24.3% vs 22.5%, 30-day respondent quit rate; P = .73) (Table 2). A separate analysis that further segmented 
those without diabetes by other chronic disease status (with vs without other chronic disease) found no significant 
difference in quit rates (diabetes group, 24.3%; group with other chronic disease, 26.5%; group without chronic disease, 
20.0%; P = .84).
However, participants with diabetes reported more weight gain in prior quit attempts than those without diabetes 
(34.2% vs 22.2% reported gaining >20 lbs; P < .05). Participants with diabetes who were successful in quitting smoking 
through the quitline were more likely to report weight gain than those who were successful and did not have diabetes, 
although results were not significant (P = .43). Amount of weight gained was also higher but not significantly so (23.2 
lbs vs 14.7 lbs; P = .20) (Table 2).
Consistent with the bivariate results, multivariable results revealed that participants with diabetes had similar odds of 
reporting tobacco abstinence at either 7 or 30 days compared with those without diabetes (OR, 0.8; 95% CI, 0.38–1.55 
and OR, 0.7, 95% CI, 0.36–1.55, respectively) after adjusting for BMI, age, sex, NRT use, weight concern, and mean 
depression score (Table 3).
The only correlate of 7-day and 30-day tobacco abstinence among the total sample was weight concern; those who 
expressed greater perceived risk of relapse due to weight gain were less likely to report abstinence (7-day OR, 0.8; 95% 
CI, 0.65–0.88; 30-day OR, 0.8; 95% CI, 0.67–0.91). However, when analysis was restricted to the subsample with 
diabetes, weight concern was not a significant predictor of quitting (OR, 0.8; 95% CI, 0.66–1.03; data not shown).
Discussion
Although tobacco quitline use is low among the general population (16), results from this study indicate that the 
proportion of tobacco users with diabetes who used the quitline was greater than their representation in the general 
statewide population. This finding is important, given that diabetes prevalence is increasing nationally and smoking is a 
behavioral risk factor that contributes both to causing and complicating the disease (23). Higher proportional use of the 
quitline among those with diabetes as compared with the general population may be the result of a concerted effort by 
the Washington State Department of Health to integrate cessation treatment referrals into state chronic disease systems 
(24). Another factor may be that diagnosis of a chronic condition, especially one related to smoking (eg, diabetes), has 
been shown to create an impetus to quit smoking (25).
In addition to use, a major finding of this study is that having diabetes did not affect quit rates, even after adjusting for 
individual differences such as age, sex, weight concern, depression, use of NRT, and BMI. Furthermore, participants 
with diabetes had similar odds of reporting tobacco abstinence compared with those without diabetes after adjusting for 
the existence of other chronic diseases, supporting evidence that chronic disease does not hinder successful cessation 
(25).
Although participants with diabetes were older, had smoked longer, and were more likely to be depressed than those 
without diabetes, these factors did not decrease their likelihood of quitting. This may be because people with diabetes 
typically have high health care use, which could mean increased contact with the health care system (26). It may also be 
due to increased pressure from providers to quit.
The perceived risk of relapse due to weight gain was associated with lower odds of reporting tobacco abstinence, even 
after controlling for differences in incidence of depression. Findings from this study indicated that participants with 
diabetes were no more likely than the comparison group to gain weight over time. However, among participants who 
reported successfully quitting smoking, those with diabetes were more likely to report that they gained weight than were 
quitters who did not have diabetes. This weight gain may be attributable to the increased prevalence of obesity and 
depression in the diabetes arm. People with diabetes have been shown to have higher rates of depression (27), and 
depression and diabetes have both been associated with reduced self-care, including nonadherence to diet, exercise, and 
medication (28). Adding smoking cessation to the equation may further increase weight gain.
Although depression can impede successful quitting (29), those with diabetes were able to quit smoking at same level as 
the comparison group, despite having elevated levels of depression. These findings suggest that depression may not 
directly impact successful quitting in those with diabetes. However, since those with and without diabetes reported 
significantly different weight gain during prior quit attempts, the relationship between depression and quitting may be 
moderated by weight changes. Given that lower levels of weight concern were a significant predictor of successful 
quitting in this study, a full mediation and moderation analysis is warranted to clarify the relationship between 
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depression, weight gain, weight concern, and quitting. When taken together, these weight-related findings suggest that 
greater efforts are needed to address weight gain in cessation treatment.
Numerous limitations should be considered when interpreting these results. First, results may not be generalizable to 
people outside of Washington State or to people who attempt to quit smoking through other treatment resources. 
Second, because the purpose of the study was to evaluate differences in use and quit rates, we matched by sex, insurance 
status, and cigarettes per day, thus limiting our ability to assess differences in these variables. Third, although only 6% 
to 10% of the initial sample refused to participate in the survey, the additional 26% to 33% who were located but not 
reached after 11 attempts might be considered passive refusals. Because of the low contact rate, it should also be noted 
that responder quit rates are tentative. Although the response rate for this study is lower than that of many clinical 
trials, it is comparable to completion rates from other telephone-based studies of quitline participants (12). Fourth, 
Medicaid fee-for-service data were not available for the entire study period. Although there is no reason to believe that 
the inclusion of additional Medicaid data would have changed these results, this is a limitation of the current study. 
Finally, diabetes diagnoses were self-reported and may underestimate the true population of quitline participants who 
have diabetes.
Despite these potential limitations, these data make an important contribution to the literature, suggesting that people 
with diabetes use the quitline and succeed at quitting at rates equal to those without diabetes, but that quit rates may be 
further enhanced by addressing weight concern and weight gain.
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Table 1. Demographics and Tobacco Use and Weight-Related 
Characteristics Among Quitline Participants With and Without 
Diabetes, Washington State, 2008
Characteristic
Diabetes No Diabetes
n % Mean (SD) n % Mean (SD)
Sex, n (%)
Female 111 67.6 NA 131 67.9 NA
Age , y
18-25 
111
1.8
51.0 (11.07) 131
12.2
44.6 (13.6)
26-40 13.5 27.5
41-60 69.4 45.8
>60 15.3 14.5
Race/ethnicity
Hispanic
109
2.7
NA
128
4.7
NA
Non-Hispanic 97.3 95.3
White
110
79.1
129
86.0
Nonwhite 20.9 14.0
Education
High school graduate or less
106
50.0
NA 129
52.7
NA
More than high school graduate 50.0 47.3
Mental health status
Depression scale (range, 0-6)
108
45.4 2.4 (1.9)
127
30.2 1.8 (2.0)
Depressive symptoms (score >3)
Anxiety scale
30.6 1.1 (1.1) 29.9 1.0 (1.1)
Percentage with panic (yes/no scale)
Other chronic diseases
Asthma
111
32.4
NA 131
19.0
NA
Chronic obstructive pulmonary disease 30.6 19.9
Heart disease 15.3 11.5
>1 of the above 8.7 10.7
Tobacco type reported at enrollment
Cigarettes
108
96.3
NA 128
97.7
NA
Other tobacco type 3.7 2.3
Smoking level (no. of cigarettes per day)
Light (1-14)
111
23.4
NA 131
29.0
NAModerate (15-20) 41.4 34.3
Heavy (≥21) 35.2 36.7
No. of years used tobacco
<20
94
13.8
NA 103
34.0
NA
≥20 86.2 66.0
Time to first cigarette
a
b
b b
b
b
b
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Characteristic
Diabetes No Diabetes
n % Mean (SD) n % Mean (SD)
≤5 min after waking 109 54.1 NA 129 52.7 NA
Use of nicotine replacement therapy
Yes 111 67.6 NA 131 75.6 NA
Body mass index (BMI)
Obese (BMI ≥30)
102
56.9
33.5 (9.5) 121
35.8
28.4 (7.7)Overweight (BMI 25.0-29.9) 30.4 267.6
Normal weight or underweight (BMI 18.0-24.9) 12.7 36.6
Perceived body weight
Very overweight
108
29.6
NA 126
12.7
NAOverweight 50.0 43.6
Normal weight or underweight 20.4 43.7
Dieting status
Not currently dieting
99
50.5
NA 120
60.9
NACurrently dieting to lose weight 27.3 18.3
Currently dieting to keep weight as it is 22.2 20.8
Physical activity level
Days per week of moderate physical activity 101 NA 3.23 (2.87) 121 NA 3.90 (2.48)
Concerns about weight gain after quitting
Scored ≥5 on a 1 to 10 Likert scale 83 62.6 NA 97 52.6 NA
Likelihood of relapse due to weight gain
Scored ≥5 on a 1 to 10 Likert scale 102 28.4 NA 115 29.6 NA
Abbreviations: SD, standard deviation; NA, not available.
P < .001.
P < .05.
BMI was calculated as weight divided by height squared multiplied by 703 ([lb/in ] × 703).
Among those who continued to smoke.
Where 1 = not concerned, and 10 = very concerned.
Table 2. Unadjusted Quit Rates and Weight Changes Among Participants 
With and Without Diabetes, Washington State, 2008
Unadjusted Quit Rates Diabetes No Diabetes
Respondent 7-day quit rate n % or mean (SD) n % or mean (SD)
Quit 111 28.8 129 26.4
Intent-to-treat 7-day quit rate
Quit 261 12.3 339 10.0
Respondent 30-day quit rate
Quit 111 24.3 129 22.5
Intent-to-treat 30-day quit rate
Quit 261 10.3 339 8.5
Weight gain in prior quit attempts
c
a
d
e
e
a
b
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Unadjusted Quit Rates Diabetes No Diabetes
Respondent 7-day quit rate n % or mean (SD) n % or mean (SD)
Mean (SD) 16.9 (24.21) 10.29 (18.0)
Gained <20 lbs
80
65.8
99
77.8
Gained ≥20 lbs 34.2 22.2
Weight change since calling the quitline
No change in weight
108
41.7
126
45.2
Gained weight 34.3 32.6
Lost weight 24.1 22.2
Weight gained, lbs, mean (SD) 19.2 (15.9) 15.4 (9.7)
Range, lbs 3–75 5–40
Weight change among quitters
No change in weight
31
29.0
33
36.4
Gained weight 51.6 36.4
Lost weight 19.3 27.3
Weight gained, lbs, mean (SD) 23.2 (22.1) 14.7 (8.0)
Among those who made a prior quit attempt.
P < .05.
Table 3. Correlates of Tobacco Cessation Among the Total Sample With and 
Without Diabetes, Washington State, 2008
Selected Characteristic
Diabetes No Diabetes
7-Day Tobacco Abstinence, OR 
(95% CI)
30-Day Tobacco Abstinence, OR 
(95% CI)
Diabetes status (diabetes vs no 
diabetes)
0.8 (0.38–1.55) 0.7 (0.36–1.55)
BMI (normal vs overweight or obese) 1.5 (0.97–2.25) 1.3 (0.84–2.00)
Age 1.0 (0.98–1.04) 1.0 (0.98–1.04)
Sex (female vs male) 2.3 (1.09–4.82) 2.0 (0.94–4.43)
NRT use 1.4 (0.63–2.93) 1.3 (0.57–2.86)
Weight concern (≥5 vs <5, on a 10 
point scale)
0.8 (0.65–0.88) 0.8 (0.67–0.91)
PHQ-2 Depression score (<3 vs >3) 1.1 (0.56–2.26) 0.9 (0.44–1.84)
Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; NRT, nicotine replacement therapy.
BMI was calculated as weight divided by height squared multiplied by 703 (lb/in × 703).
Response options to the 2 PHQ-2 items are on a 0-3 severity scale. We computed the mean score (0 minimum possible, 6 
maximum possible).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or 
the authors' affiliated institutions.
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